Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients

NCT04922593 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.

NCT NCT04922593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04922593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the PK Profiles of LY03010 and Relative Bioavailability at Steady-state of LY03010 Versus INVEGA SUSTENNA in Schizophrenia Patients
Lead sponsor
Luye Pharma Group Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 13, 2021
Completion date
April 15, 2022
Enrollment
281 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

antipsychotic agents, central nervous system depressants, mental disorders, molecular mechanisms of pharmacological action, mood disorders, neurotransmitter agents, physiological effects of drugs, psychotic disorders, psychotropic drugs, schizophrenia, schizophrenia spectrum, tranquilizing agents